FAS and pulmonary arterial hypertension: Singh et al. reported that in a monocrotaline-induced PAH model, there was an increase in RVP of PAH rats (about 55 mmHg), which was significantly reversed by FAS inhibition (C75 treatment groups were about 40 mmHg) [10].